Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, there is clinical evidence that tirzepatide (Mounjaro) can reduce blood pressure in people with obesity or excess weight, mainly because significant weight loss tends to lower blood pressure on its own. In trials, participants who lost the most weight on tirzepatide also saw meaningful reductions in systolic blood pressure. That said, Mounjaro is licensed for weight management, not as a blood pressure treatment — and whether it helps any individual person is a clinical question, not a given. These are prescription-only medicines that require a proper assessment before a prescriber can determine whether they are suitable for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people searching this question are hoping to hear that tirzepatide is a two-for-one: a weight-loss medicine that also treats hypertension. The picture is more nuanced. Mounjaro is a dual GIP and GLP-1 receptor agonist, it works primarily on appetite regulation and blood-sugar control, slowing gastric emptying and increasing feelings of fullness. It is not prescribed for hypertension, and no UK licence covers that indication.
The blood pressure effect seen in clinical data is almost entirely weight-mediated. Carrying excess weight raises blood pressure through a cluster of mechanisms: increased cardiac output, heightened sympathetic nervous system activity, and changes in kidney function. Lose a significant amount of weight, and those pressures ease. That is what happens in trials of tirzepatide, and the relationship between tirzepatide and blood pressure reduction tracks this pattern closely. So the answer to "can Mounjaro help with blood pressure?" is: yes, indirectly, through the weight loss it produces, not because it acts on blood vessels or heart rate in a therapeutically targeted way.
This distinction matters practically. If your blood pressure is the primary clinical concern, your GP will want to address it directly, whether or not you are also losing weight.
SURMOUNT-1, the pivotal phase 3 trial of tirzepatide for weight management, involved thousands of adults with obesity. Participants who reached the 15mg maintenance dose lost an average of around 20–21% of body weight over 72 weeks, as reported in the New England Journal of Medicine. Alongside that, the trial recorded reductions in systolic blood pressure: in the highest-dose group, average systolic readings fell by roughly 6–7 mmHg compared with placebo. That is not a trivial number, for context, a 5 mmHg reduction in systolic pressure is associated in population studies with a meaningfully lower risk of major cardiovascular events over time.
The size of the blood pressure drop correlated with the degree of weight lost. Participants who lost more weight tended to see larger falls in blood pressure. If you want to understand the full picture of how Mounjaro affects blood pressure, including what the data shows across different patient groups, we cover that in detail separately. It also explains why individual results vary: someone who loses 12% of body weight will likely see a different blood pressure response than someone who loses 22%.
NICE's appraisal of tirzepatide (published as TA1026) noted improvements in cardiometabolic risk factors including blood pressure and lipid profiles alongside weight reduction, which factored into the committee's positive recommendation for the medicine.
This is probably the most practically important part for many readers. If you are taking antihypertensive tablets and you start losing significant amounts of weight, your blood pressure can fall further than expected. That is generally good news, but it can occasionally mean that your existing medication becomes too strong for your new physiology, leading to blood pressure that dips too low. Low blood pressure on tirzepatide is worth understanding separately.
Symptoms of blood pressure that has dropped too far include dizziness when standing, light-headedness, or feeling faint, particularly when moving from sitting to standing. If any of those appear, you need your prescriber or GP involved promptly. A quick habit worth building: check your blood pressure at a pharmacy machine or with a home cuff every few weeks as your weight changes. It takes under a minute and gives you and your clinical team something concrete to act on. Interactions between tirzepatide and antihypertensive medicines are a straightforward conversation to have at your consultation, and your prescriber will factor your current medication list into their assessment.
If you want to understand how specific combinations work, taking Mounjaro alongside blood pressure tablets is covered in more detail elsewhere on our site. The short version: it is generally possible, but requires clinical oversight, because dose adjustments may become necessary as your weight changes.
Mounjaro is a prescription-only medicine. A prescriber cannot simply hand it over on request, they need to review your full health picture, including any existing cardiovascular or blood pressure conditions and the medicines you already take. That review exists to protect you, not to create unnecessary barriers.
At nume, every consultation is read by a GPhC-registered Independent Prescriber. Not a chatbot, not an automated scoring system, a real clinician reads your answers. Our clinical team is available to answer questions through aftercare seven days a week, which matters if your blood pressure readings change meaningfully once treatment starts. Some patients also ask whether it is possible to syndicate Mounjaro with others to share costs, and our team can explain how treatment access works through a regulated service. You can read more about how we work on our about page, or explore the full range of weight-loss treatment options to see what a consultation covers.
The NHS guidance on weight management injections also recommends that patients on antihypertensive medicines have their blood pressure monitored during treatment, this is standard practice, not optional extra caution.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.